235 related articles for article (PubMed ID: 25635758)
21. A >or=1 log rise in RQ-PCR transcript levels defines molecular relapse in core binding factor acute myeloid leukemia and predicts subsequent morphologic relapse.
Lane S; Saal R; Mollee P; Jones M; Grigg A; Taylor K; Seymour J; Kennedy G; Williams B; Grimmett K; Griffiths V; Gill D; Hourigan M; Marlton P
Leuk Lymphoma; 2008 Mar; 49(3):517-23. PubMed ID: 18297529
[TBL] [Abstract][Full Text] [Related]
22. Complex karyotype, older age, and reduced first-line dose intensity determine poor survival in core binding factor acute myeloid leukemia patients with long-term follow-up.
Mosna F; Papayannidis C; Martinelli G; Di Bona E; Bonalumi A; Tecchio C; Candoni A; Capelli D; Piccin A; Forghieri F; Bigazzi C; Visani G; Zambello R; Zanatta L; Volpato F; Paolini S; Testoni N; Gherlinzoni F; Gottardi M
Am J Hematol; 2015 Jun; 90(6):515-23. PubMed ID: 25753065
[TBL] [Abstract][Full Text] [Related]
23. Hematopoietic stem cell transplantation for core binding factor acute myeloid leukemia: t(8;21) and inv(16) represent different clinical outcomes.
Kuwatsuka Y; Miyamura K; Suzuki R; Kasai M; Maruta A; Ogawa H; Tanosaki R; Takahashi S; Koda K; Yago K; Atsuta Y; Yoshida T; Sakamaki H; Kodera Y
Blood; 2009 Feb; 113(9):2096-103. PubMed ID: 19126873
[TBL] [Abstract][Full Text] [Related]
24. Mutations in the CCND1 and CCND2 genes are frequent events in adult patients with t(8;21)(q22;q22) acute myeloid leukemia.
Eisfeld AK; Kohlschmidt J; Schwind S; Nicolet D; Blachly JS; Orwick S; Shah C; Bainazar M; Kroll KW; Walker CJ; Carroll AJ; Powell BL; Stone RM; Kolitz JE; Baer MR; de la Chapelle A; Mrózek K; Byrd JC; Bloomfield CD
Leukemia; 2017 Jun; 31(6):1278-1285. PubMed ID: 27843138
[TBL] [Abstract][Full Text] [Related]
25. [Genetic abnormalities in core binding factor acute myeloid leukemia].
Ishikawa Y
Rinsho Ketsueki; 2017; 58(8):991-998. PubMed ID: 28883285
[TBL] [Abstract][Full Text] [Related]
26. Poor outcome in a pediatric patient with acute myeloid leukemia associated with a variant t(8;21) and trisomy 6.
Kelly MJ; Meloni-Ehrig AM; Manley PE; Altura RA
Cancer Genet Cytogenet; 2009 Feb; 189(1):48-52. PubMed ID: 19167612
[TBL] [Abstract][Full Text] [Related]
27. Prognostic factor analysis in core-binding factor-positive acute myeloid leukemia.
Jung HA; Maeng CH; Park S; Kim SJ; Kim K; Jang JH; Jung CW
Anticancer Res; 2014 Feb; 34(2):1037-45. PubMed ID: 24511052
[TBL] [Abstract][Full Text] [Related]
28. Acute myeloid leukaemia with t(8;21)(q22;q22.3) and loss of the X chromosome.
Mohamed M; Dun K
BMJ Case Rep; 2015 Aug; 2015():. PubMed ID: 26250367
[TBL] [Abstract][Full Text] [Related]
29. [Molecular pathogenesis and treatment of core binding factor-acute myeloid leukemia].
Ishikawa Y
Rinsho Ketsueki; 2018; 59(10):1997-2006. PubMed ID: 30305502
[TBL] [Abstract][Full Text] [Related]
30. Prognostic value of minimal residual disease (MRD) in acute myeloid leukemia (AML) with favorable cytogenetics [t(8;21) and inv(16)].
Perea G; Lasa A; Aventín A; Domingo A; Villamor N; Queipo de Llano MP; Llorente A; Juncà J; Palacios C; Fernández C; Gallart M; Font L; Tormo M; Florensa L; Bargay J; Martí JM; Vivancos P; Torres P; Berlanga JJ; Badell I; Brunet S; Sierra J; Nomdedéu JF;
Leukemia; 2006 Jan; 20(1):87-94. PubMed ID: 16281071
[TBL] [Abstract][Full Text] [Related]
31. Detection and treatment of molecular relapse in acute myeloid leukemia with RUNX1 (AML1), CBFB, or MLL gene translocations: frequent quantitative monitoring of molecular markers in different compartments and correlation with WT1 gene expression.
Doubek M; Palasek I; Pospisil Z; Borsky M; Klabusay M; Brychtova Y; Jurcek T; Jeziskova I; Krejci M; Dvorakova D; Mayer J
Exp Hematol; 2009 Jun; 37(6):659-72. PubMed ID: 19463768
[TBL] [Abstract][Full Text] [Related]
32. Combination of dasatinib with chemotherapy in previously untreated core binding factor acute myeloid leukemia: CALGB 10801.
Marcucci G; Geyer S; Laumann K; Zhao W; Bucci D; Uy GL; Blum W; Eisfeld AK; Pardee TS; Wang ES; Stock W; Kolitz JE; Kohlschmidt J; Mrózek K; Bloomfield CD; Stone RM; Larson RA
Blood Adv; 2020 Feb; 4(4):696-705. PubMed ID: 32092139
[TBL] [Abstract][Full Text] [Related]
33. Simple method for detection of MYH11 DNA rearrangements in patients with inv(16)(p13q22) and acute myeloid leukemia.
van der Reijden BA; Martinet D; Dauwerse JG; Giles RH; Wessels JW; Beverstock GC; Smit B; Mühlematter D; Jotterand Bellomo M; Gabert J; Lafage-Pochitaloff M; Reiffers J; Bilhou-Nabera C; van Ommen GJ; Hagemeijer A; Breuning MH
Leukemia; 1996 Sep; 10(9):1459-62. PubMed ID: 8751463
[TBL] [Abstract][Full Text] [Related]
34. Acute myeloid leukemia with a RUNX1-RUNX1T1 t(1;21;8)(q21;q22;q22) novel variant: a case report and review of the literature.
Kim H; Moon HW; Hur M; Yun YM; Lee MH
Acta Haematol; 2011; 125(4):237-41. PubMed ID: 21325813
[TBL] [Abstract][Full Text] [Related]
35. Core-binding factor acute myeloid leukemia: can we improve on HiDAC consolidation?
Paschka P; Döhner K
Hematology Am Soc Hematol Educ Program; 2013; 2013():209-19. PubMed ID: 24319183
[TBL] [Abstract][Full Text] [Related]
36. Heterogeneity in CBF beta/MYH11 fusion messages encoded by the inv(16)(p13q22) and the t(16;16)(p13;q22) in acute myelogenous leukemia.
Shurtleff SA; Meyers S; Hiebert SW; Raimondi SC; Head DR; Willman CL; Wolman S; Slovak ML; Carroll AJ; Behm F
Blood; 1995 Jun; 85(12):3695-703. PubMed ID: 7780153
[TBL] [Abstract][Full Text] [Related]
37. RNA sequencing as an alternative tool for detecting measurable residual disease in core-binding factor acute myeloid leukemia.
Kim T; Moon JH; Ahn JS; Ahn SY; Jung SH; Yang DH; Lee JJ; Shin MG; Choi SH; Lee JY; Tyndel MS; Lee HY; Kim KH; Cai Y; Lee YJ; Sohn SK; Min YH; Cheong JW; Kim HJ; Zhang Z; Kim DDH
Sci Rep; 2020 Nov; 10(1):20119. PubMed ID: 33208771
[TBL] [Abstract][Full Text] [Related]
38. Prevalence and prognostic significance of c-KIT mutations in core binding factor acute myeloid leukemia: a comprehensive large-scale study from a single Chinese center.
Qin YZ; Zhu HH; Jiang Q; Jiang H; Zhang LP; Xu LP; Wang Y; Liu YR; Lai YY; Shi HX; Jiang B; Huang XJ
Leuk Res; 2014 Dec; 38(12):1435-40. PubMed ID: 25449688
[TBL] [Abstract][Full Text] [Related]
39. Common gene expression signatures in t(8;21)- and inv(16)-acute myeloid leukaemia.
Ichikawa H; Tanabe K; Mizushima H; Hayashi Y; Mizutani S; Ishii E; Hongo T; Kikuchi A; Satake M
Br J Haematol; 2006 Nov; 135(3):336-47. PubMed ID: 16989659
[TBL] [Abstract][Full Text] [Related]
40. Minimal residual disease monitoring in t(8;21) acute myeloid leukemia based on RUNX1-RUNX1T1 fusion quantification on genomic DNA.
Duployez N; Nibourel O; Marceau-Renaut A; Willekens C; Helevaut N; Caillault A; Villenet C; Celli-Lebras K; Boissel N; Jourdan E; Dombret H; Figeac M; Preudhomme C; Renneville A
Am J Hematol; 2014 Jun; 89(6):610-5. PubMed ID: 24616160
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
